Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) by 41.46 percent. The company reported quarterly sales of $2.88 million which missed the analyst consensus estimate of $4.04 million by 28.74 percent.